2형 당뇨병 시장 규모, 점유율, 성장 분석 : 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Type 2 Diabetes Market size was valued at USD 36.7 Billion in 2024 and is poised to grow from USD 39.53 Billion in 2025 to USD 71.67 Billion by 2033, growing at a CAGR of 7.72% during the forecast period (2026-2033).

The global type 2 diabetes market is experiencing significant growth, primarily driven by the surging prevalence of the condition worldwide. This escalating demand for effective treatments has prompted pharmaceutical companies to innovate and introduce new therapies. Notable advancements include sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, which have emerged as preferred options due to their efficacy and reduced side effects. However, a gap remains in patient awareness regarding these new treatments, potentially hindering their adoption. The increasing need for affordable and advanced diabetes management solutions creates substantial opportunities for market expansion. Furthermore, technological advancements, including mobile health applications and cloud-based solutions, are revolutionizing treatment delivery, making effective options more accessible to patients globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Type 2 Diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Type 2 Diabetes Market Segments Analysis

Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Distribution Channel, End User, and Region. Based on Drug Class, the market is segmented into Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Biguanides, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Based on End User, the market is segmented into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Type 2 Diabetes Market

One of the key market drivers for the global Type 2 diabetes market is the increasing prevalence of obesity and sedentary lifestyles among populations worldwide. As obesity rates rise, the incidence of Type 2 diabetes escalates, prompting a growing demand for effective treatments and management solutions. This surge in cases is further fueled by genetic factors and dietary habits, leading to heightened awareness and proactive health measures. Consequently, pharmaceutical companies and healthcare providers are investing significantly in research and development of innovative therapies, monitoring devices, and educational programs, creating a robust market landscape focused on combating this chronic condition.

Restraints in the Global Type 2 Diabetes Market

One key market restraint for the global Type 2 diabetes market is the rising prevalence of drug affordability concerns among patients and healthcare systems. The increasing cost of diabetes management medications, including insulin and oral antidiabetic agents, poses significant barriers, particularly in low and middle-income regions. This financial strain can lead to non-adherence to prescribed treatments, ultimately resulting in poorer health outcomes. Moreover, healthcare providers may face limitations in prescribing optimal therapies due to budget constraints, thereby hindering the market's growth potential and innovation in new, effective treatment options for Type 2 diabetes.

Market Trends of the Global Type 2 Diabetes Market

The global Type 2 Diabetes market is experiencing a significant shift towards remote monitoring and digital health solutions, driven by the integration of wearable technologies and mobile applications. These innovations empower patients to continuously monitor their glucose levels and share real-time data with healthcare providers, fostering proactive disease management. Enhanced tracking of blood sugar levels, medication adherence, and overall health not only improves patient outcomes but also contributes to reduced healthcare costs. Furthermore, this trend stimulates increased patient engagement, ultimately transforming diabetes care into a more personalized and efficient experience, which reflects a broader movement towards technological integration in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Type 2 Diabetes Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Dipeptidyl Peptidase-4 Inhibitors
• Glucagon-like Peptide 1 Receptor Agonists
• Biguanides
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
• Others

Global Type 2 Diabetes Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral

Global Type 2 Diabetes Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Type 2 Diabetes Market Size by End User & CAGR (2026-2033)

• Market Overview
• Homecare Settings
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Global Type 2 Diabetes Market Size & CAGR (2026-2033)

• North America (Drug Class, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations